Nutrition, Inflammation, and Leptin Levels in Aging and Frailty

Hubbard, Ruth E.; O'Mahony, M Sinead; Calver, Brian L.; Woodhouse, Ken

doi:10.1111/j.1532-5415.2007.01548.x

Cited by 100 publications

(58 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hubbard et al assessed frailty characteristics and cytokine levels in 3 groups of patients: 1) 40 patients housed in an inpatient geriatric ward (median age, 85 years), 2) 40 patients attending a day hospital (median age, 83 years), and 3) 30 healthy controls (median age, 23 years). 99 Increases in IL-6 and CRP were paralleled by a decrease in BMI and increasing frailty. In separate studies, increases in IL-6 and CRP have been associated with other domains of the frailty assessment, including poor walking speed and grip strength.…”

Section: Biological Markers Of Frailtymentioning

confidence: 98%

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

Pal¹,

Katheria²,

Hurria³

2010

CA: A Cancer Journal for Clinicians

218

View full text Add to dashboard Cite

The majority of cancer incidence and mortality occurs in individuals aged older than 65 years, and the number of older adults with cancer is projected to significantly increase secondary to the aging of the US population. As such, understanding the changes accompanying age in the context of the cancer patient is of critical importance. Agerelated changes can impact tolerance of anticancer therapy and can shift the overall risk-benefit ratio of such treatment. A challenge in implementing evidence-based approaches in older adults is the under-representation of this group in oncology clinical trials. In addition, although older adults are particularly vulnerable to the side effects of cancer therapy, few oncology studies to date have incorporated a measure of health status other than the Eastern Cooperative Oncology Group or Karnofsky performance scales. Novel metrics such as frailty indices or the geriatric assessment recognize heterogeneity among older adults, and may allow for risk-adapted approaches to therapy. It is increasingly recognized that several laboratory markers may predict morbidity and mortality in older adults; these biologic variables may further aid in stratifying this group of patients based on risk. This review describes key studies from the geriatric literature that provide principles for assessing health status in the older patient, and ways that these principles can be applied to oncology care in an older population are proposed. CA Cancer J Clin 2010;60:120-132.

show abstract

Section: Biological Markers Of Frailtymentioning

confidence: 98%

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

Pal¹,

Katheria²,

Hurria³

2010

CA: A Cancer Journal for Clinicians

218

View full text Add to dashboard Cite

show abstract

“…Conceivably, this could enhance immobility and cachexia associated with both HF and frailty. Clearly, future research will be required to decipher the role inflammation plays in the complex interaction between HF, frailty, and cachexia (Hubbard et al ., 2008). …”

Section: How Aging Frailty and Hf Interact To Induce Inflammationmentioning

confidence: 99%

Pathophysiology of heart failure and frailty: a common inflammatory origin?

et al. 2017

View full text Add to dashboard Cite

SummaryFrailty, a clinical syndrome that typically occurs in older adults, implies a reduced ability to tolerate biological stressors. Frailty accompanies many age‐related diseases but can also occur without overt evidence of end‐organ disease. The condition is associated with circulating inflammatory cytokines and sarcopenia, features that are shared with heart failure (HF). However, the biological underpinnings of frailty remain unclear and the interaction with HF is complex. Here, we describe the inflammatory pathophysiology that is associated with frailty and speculate that the inflammation that occurs with frailty shares common origins with HF. We discuss the limitations in investigating the pathophysiology of frailty due to few relevant experimental models. Leveraging current therapies for advanced HF and current known therapies to address frailty in humans may enable translational studies to better understand the inflammatory interactions between frailty and HF.

show abstract

“…What about genetics -is frailty explained by the disposable soma theory (4) and programmed cell death? Then there are the biomarkers, including not only sarcopaenia and osteopaenia, but vitamin D, interleukins and C-reactive peptide (5,6). These measures, along with the battery of frailty rating scores and other health measurement scales are describing the syndrome of frailty, but not diagnosing it.…”

mentioning

confidence: 99%

Defining frailty — the holy grail of geriatric medicine

Conroy

2009

The Journal of nutrition, health and aging

View full text Add to dashboard Cite

Nutrition, Inflammation, and Leptin Levels in Aging and Frailty

Cited by 100 publications

References 30 publications

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

Pathophysiology of heart failure and frailty: a common inflammatory origin?

Defining frailty — the holy grail of geriatric medicine

Contact Info

Product

Resources

About